Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2024-07-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于注销部分股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of a portion of stock options under its 2022 stock option incentive plan. It details the number of stock options cancelled, reasons for cancellation (such as employees leaving and unmet performance targets), approvals by the board and supervisory committee, and legal opinions. The document is a formal disclosure about changes in stock options but does not contain financial statements or detailed financial performance data. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting result announcement. The content fits best with announcements related to share-based compensation changes, which are typically classified under Regulatory Filings (RNS) as they do not fit other more specific categories and are regulatory disclosures about corporate actions affecting equity instruments.
2024-07-19 Chinese
国浩律师（深圳）事务所关于公司2022年股票期权激励计划注销部分股票期权之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain stock options under the 2022 stock option incentive plan of a company. It details the approval and authorization process, reasons for cancellation, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to stock option cancellations. This fits best under Regulatory Filings (RNS) as it is a legal compliance document and does not constitute a standalone audit report or financial report. The document length is over 6000 characters and contains detailed legal content, not just an announcement or certification, so it is not RPA or a certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-07-19 Chinese
第五届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 20th meeting of the 5th Board of Directors of the company. It details the meeting attendance, the agenda items discussed, and the voting results on stock option adjustments, stock option cancellations, and cancellation of restricted stock. The document is a board meeting resolution announcement, not a full management report or financial statement. It does not contain financial data or detailed management discussion but focuses on board decisions and approvals. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1705 characters), and it is not an announcement of a report publication but a substantive announcement of board decisions.
2024-07-19 Chinese
第五届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th meeting of the 5th Supervisory Board of the company. It details the meeting attendance, the approval of adjustments to stock option exercise prices, cancellation of some stock options, and invalidation of certain restricted stocks. It references related announcements published on a regulatory disclosure website but does not itself contain financial statements or detailed financial data. The document is primarily a corporate governance announcement about supervisory board decisions and stock incentive plan adjustments. It is not an annual report, earnings release, or financial report. It is not a proxy solicitation or voting results announcement. It is not a regulatory filing of officer certifications or legal proceedings. The best fitting category is Board/Management Information (MANG), as it concerns supervisory board meeting resolutions and governance-related decisions about stock incentives.
2024-07-19 Chinese
国浩律师（深圳）事务所关于公司2021年限制性股票激励计划作废部分已授予尚未归属的第二类限制性股票之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted shares under a 2021 restricted stock incentive plan of a company. It details the approval and authorization process, legal compliance, and the rationale for the cancellation of shares due to unmet performance targets. The document is a standalone legal opinion related to a specific corporate action (stock incentive plan adjustments) and does not contain financial statements or earnings data. It is not an annual report, earnings release, or management discussion. It is not a regulatory announcement or a brief notice but a detailed legal opinion. Therefore, it fits best under the category of Audit Report / Information (AR), as it involves legal and compliance verification related to corporate stock incentive plans and their adjustments, which is consistent with audit or legal opinion reports on corporate actions. FY 2023
2024-07-19 Chinese
国浩律师（深圳）事务所关于公司调整2021年限制性股票激励计划授予及回购价格和2022年股票期权股票激励计划行权价格之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to the 2021 restricted stock incentive plan and the 2022 stock option incentive plan of a company. It details the approval procedures, adjustments to grant and repurchase prices, and compliance with relevant laws and regulations. The document is a standalone legal opinion related to stock incentive plans and does not contain financial statements or earnings data. It is not an announcement of a report but a legal opinion letter. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related legal or regulatory compliance documents excluding full annual or interim reports. FY 2024
2024-07-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.